NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
2/8 — Basic
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TARKA is a fixed-dose combination tablet containing trandolapril (ACE inhibitor) and verapamil hydrochloride (calcium channel blocker) in extended-release formulation. It is indicated for hypertension management, leveraging dual mechanisms to reduce blood pressure through ACE inhibition and coronary/peripheral vasodilation. The combination allows for synergistic cardiovascular protection in patients requiring both agents.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling contraction in brand team size and shift toward generic defense strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka® Fixed Combination in Patients With Essential Hypertension
Started Apr 2010
3,828 enrolled
Essential Hypertension
Effectiveness and Tolerability of Tarka® in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus
Started Oct 2007
15,436 enrolled
Hypertension
Russian Study of the Efficacy and Safety of Tarka in Patients With Hypertension
Started Jun 2004
120 enrolled
Hypertension
Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)
Started Mar 2004
280 enrolled
HypertensionMetabolic Syndrome
Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)
Started Jan 2004
357 enrolled
HypertensionDiabetesProteinuria
Worked on TARKA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.